Amphastar P (AMPH) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03209R1032

Injections, Inhalers, Nasal Sprays

Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company that develops, manufactures, markets, and sells a wide range of generic and proprietary products, including injectable, inhalation, and intranasal medications. The company operates in the United States, China, and France, catering to a diverse customer base.

The company's product portfolio includes BAQSIMI, a nasal spray used to treat severe hypoglycemia, as well as Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild asthma symptoms. Additionally, Amphastar offers Enoxaparin, a medication used to prevent and treat deep vein thrombosis, and REXTROVY and Naloxone for opioid overdose.

Amphastar's product line also includes Glucagon for injection emergency kits, Cortrosyn for use as a diagnostic agent in patients with adrenocortical insufficiency, and Amphadase, an injection used to absorb and disperse other injected drugs. The company also offers Epinephrine injection for allergic reactions, Lidocaine jelly for urological procedures, and Lidocaine topical solution for various medical procedures.

Furthermore, the company provides Phytonadione injection, a vitamin K1 injection for newborn babies, as well as emergency syringe products, morphine injection for use with patient-controlled analgesia pumps, and Lorazepam injection for surgery and medical procedures. Other products include Neostigmine methylsulfate injection for myasthenia gravis, Isoproterenol hydrochloride injection for mild heart block, Ganirelix Acetate injection for inhibiting premature luteinizing hormone surges, and Vasopressin to increase blood pressure.

Amphastar also distributes recombinant human insulin APIs and porcine insulin API, and is actively developing generic product candidates, including injectable, inhalation, and analytical technologies, as well as biosimilar product candidates and intranasal epinephrine for allergic reactions. Founded in 1996, the company is headquartered in Rancho Cucamonga, California, and can be found online at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Amphastar P (AMPH) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Amphastar P (AMPH) - Stock Price & Dividends

AMPH Stock Overview

Market Cap in USD 2,012m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2014-06-25

AMPH Stock Ratings

Growth 5y 37.6
Fundamental 65.0
Dividend -
Rel. Performance vs Sector -3.67
Analysts 4.00/5
Fair Price Momentum 46.07 USD
Fair Price DCF 90.20 USD

AMPH Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

AMPH Growth Ratios

Growth 12m -27.33%
Growth Correlation 12m -47%
Growth Correlation 3m -14%
CAGR 5y 14.24%
CAGR/Mean DD 5y 0.87
Sharpe Ratio 12m -0.76
Alpha vs SP500 12m -46.20
Beta vs SP500 5y weekly 0.64
ValueRay RSI 39.74
Volatility GJR Garch 1y 41.55%
Price / SMA 50 -2.43%
Price / SMA 200 -16.91%
Current Volume 258.8k
Average Volume 20d 325.8k

External Links for AMPH Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of AMPH stocks?
As of June 18, 2024, the stock is trading at USD 40.54 with a total of 258,824 shares traded.
Over the past week, the price has changed by -2.64%, over one month by -6.76%, over three months by -5.39% and over the past year by -26.33%.
What are the forecast for AMPH stock price target?
According to ValueRays Forecast Model, AMPH Amphastar P will be worth about 50.3 in June 2025. The stock is currently trading at 40.54. This means that the stock has a potential upside of +24.15%.
Issuer Forecast Upside
Wallstreet Target Price 63.3 56.0
Analysts Target Price 69 70.2
ValueRay Target Price 50.3 24.1